Tackling immunosuppression by Neisseria gonorrhoeae to facilitate vaccine design
Rebekah A. Jones,Fidel Ramirez-Bencomo,Gail Whiting,Min Fang,Hayley Lavender,Kacper Kurzyp,Angela Thistlethwaite,Lenka Stejskal,Smruti Rashmi,Ann E. Jerse,Ana Cehovin,Jeremy P. Derrick,Christoph M. Tang
DOI: https://doi.org/10.1371/journal.ppat.1012688
IF: 7.464
2024-11-18
PLoS Pathogens
Abstract:Gonorrhoea, caused by Neisseria gonorrhoeae , is a common sexually transmitted infection. Increasing multi-drug resistance and the impact of asymptomatic infections on sexual and reproductive health underline the need for an effective gonococcal vaccine. Outer membrane vesicles (OMVs) from Neisseria meningitidis induce modest cross-protection against gonococcal infection. However, the presence of proteins in OMVs derived from N . gonorrhoeae that manipulate immune responses could hamper their success as a vaccine. Here we modified two key immunomodulatory proteins of the gonococcus; RmpM, which can elicit 'blocking antibodies', and PorB, an outer membrane porin which contributes to immunosuppression. As meningococcal PorB has adjuvant properties, we replaced gonococcal PorB with a meningococcal PorB. Immunisation with OMVs from N . gonorrhoeae lacking rmpM and expressing meningococcal porB elicited higher antibody titres against model antigens in mice compared to OMVs with native PorB. Further, a gonococcal protein microarray revealed stronger IgG antibody responses to a more diverse range of antigens in the Nm PorB OMV immunised group. Finally, meningococcal PorB OMVs resulted in a Th1-skewed response, exemplified by increased serum IgG2a antibody responses and increased IFNɣ production by splenocytes from immunised mice. In summary, we demonstrate that the replacement of PorB in gonococcal OMVs enhances immune responses and offers a strategy for gonococcal vaccine development. Neisseria gonorrhoeae is the bacterium that causes the sexually transmitted infection gonorrhoea. Gonorrhoea is a public health concern due to the bacterium developing resistance to numerous antibiotics, leading to the prospect of untreatable gonorrhoea infections. Untreated gonorrhoea causes severe complications, particularly impacting reproductive health. So far, no gonorrhoea-specific vaccine is available. N . gonorrhoeae vaccine efforts focus on optimising outer membrane vesicles (OMVs). However, the success of this approach may be hampered by the presence of immunomodulatory proteins in N . gonorrhoeae OMVs. Here we show that two key immunomodulatory proteins; the major outer membrane porin, PorB, and its stabilising protein, RmpM likely contribute to the lack of success of a gonorrhoea OMV-based vaccine. We improved immune responses to gonorrhoea OMVs by genetically modifying N . gonorrhoeae to produce OMVs lacking RmpM and containing a PorB replacement. Moving forwards, the modified OMVs represent a promising platform for a vaccine against gonorrhoea.
microbiology,virology,parasitology